Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma. Issue 2 (February 2020)

• Record Type: Journal Article
• Authors: Gholamin, Sharareh; Youssef, Osama A; Rafat, Marjan; Esparza, Rogelio; Kahn, Suzana; Shahin, Maryam; Giaccia, Amato J; Graves, Edward E; Weissman, Irving; Mitra, Siddhartha; Cheshier, Samuel H
• Is Part Of: Innate immunity. Volume 26:Issue 2(2020:Feb.)
• Page Start: 130
• Page End: 137
• Publication Date: 2020-02
• Subjects: Glioblastoma -- anti-CD47 -- irradiation -- temozolomide -- phagocytosis -- macrophages; Natural immunity -- Periodicals; Endotoxins -- Periodicals; 616.07905
• DOI: 10.1177/1753425919876690
• Languages: English
• ISSNs: 1753-4259

Abstract

Irradiation and temozolomide (TMZ) chemotherapy are the current standard treatments for glioblastoma multiforme (GBM), but they are associated with toxicity and limited efficacy. Recently, these standard therapies have been used to enhance immunotherapy against GBM. Immunotherapy using the anti-CD47 (immune checkpoint inhibitor) treatment has shown promise in treating multiple tumor types, including GBM. The goal of this current work was to test whether irradiation or TMZ chemotherapy could enhance anti-CD47 treatment against GBM. Our results showed that irradiation and TMZ each significantly enhanced anti-CD47-mediated phagocytosis of GBM cells in vitro . Furthermore, mice engrafted with human GBM that received anti-CD47 combined with focal irradiation or TMZ treatment showed a significant increase in the survival rate compared to those that received a single treatment. The tumor growth in mice that received both anti-CD47 and irradiation was significantly less than that of groups that received either anti-CD47 or focal irradiation. The results from this study may support future use of anti-CD47 treatment in combination with irradiation or chemotherapy to enhance the therapeutic efficacy of GBM treatment.